Topical delivery of aceclofenac: Challenges and promises of novel drug delivery systems

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Raza, Kaisar ^a   Kumar, Manish ^a   Kumar, Pramod ^a   Malik, Ruchi ^a   Sharma, Gajanand ^b   Kaur, Manmeet ^b   Katare, O P ^b  

^a CENTRAL UNIVERSITY OF RAJASTHAN   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; BILOSOME; EMULSOME; ETHOSOME; INVASOME; LAYEROSOME; LIPID EMULSION; LIPOSOME; NIOSOME; PHARMACOSOME; SOLID LIPID NANOPARTICLE; TRANSFERSOME; UNCLASSIFIED DRUG; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT;

DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; HUMAN; MICELLE; MICROEMULSION; NANOEMULSION; OSTEOARTHRITIS; PARTICULATE MATTER; PHOSPHOLIPID BASED MICELLE; POLYMERIC MICELLE; REVIEW; RISK BENEFIT ANALYSIS; SKIN PENETRATION; TOPICAL TREATMENT; TRANSCYTOSIS; ANALOGS AND DERIVATIVES; COMPLICATION; INFLAMMATION; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG DELIVERY SYSTEMS; INFLAMMATION; OSTEOARTHRITIS;

EID: 84904111927     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/406731     Document Type: Review

References (89)

1. Woolf A. D., Pfleger B., Burden of major musculoskeletal conditions. Bulletin of the World Health Organization 2003 81 9 646 656 2-s2.0-0141920503 (Pubitemid 37254686)
2. Altman R. D., The syndrome of osteoarthritis. Journal of Rheumatology 1997 24 4 766 767 2-s2.0-0030950973 (Pubitemid 27146098)
3. Reginster J., The prevalence and burden of arthritis. Rheumatology 2002 41 1 3 6 2-s2.0-0036100769 (Pubitemid 34537826)
4. Jordan K. M., Arden N. K., Doherty M., Bannwarth B., Bijlsma J. W. J., Dieppe P., Gunther K., Hauselmann H., Herrero-Beaumont G., Kaklamanis P., Lohmander S., Leeb B., Lequesne M., Mazieres B., Martin-Mola E., Pavelka K., Pendleton A., Punzi L., Serni U., Swoboda B., Verbruggen G., Zimmerman-Gorska I., Dougados M., EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Annals of the Rheumatic Diseases 2003 62 12 1145 1155 2-s2.0-10744224265 10.1136/ard.2003.011742 (Pubitemid 37500619)
5. Moore R. A., Tramèr M. R., Carroll D., Wiffen P. J., McQuay H. J., Quantitive systematic review of topically applied non-steroidal anti-inflammatory drugs. The British Medical Journal 1998 316 7128 333 338 2-s2.0-0032583624 (Pubitemid 28121255)
6. Pavelka K., A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Current Medical Research and Opinion 2012 28 1 163 178 2-s2.0-84855924570 10.1185/03007995.2011.649848
7. Grau M., Montero J. L., Guasch J., Felipe A., Carrasco E., Juliá S., The pharmacological profile of aceclofenac, a new nonsteroidal antiinflammatory and analgesic drug. Agents and Actions Supplements 1991 32 125 129 2-s2.0-0025984227
8. Shavi G. V., Nayak U., Averineni R. K., Arumugam K., Meka S. R., Nayanabhirama U., Sureshwar P., Multiparticulate drug delivery system of aceclofenac: development and in vitro studies. Drug Development and Industrial Pharmacy 2009 35 2 252 258 2-s2.0-60749108368 10.1080/03639040802277680
9. Manu C. U., Nonaqueous Liquid Parenteral Aceclofenac Formulation 2006 Venus Remedies Limited
10. Brogden R. N., Wiseman L. R., Aceclofenac: a review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs 1996 52 1 113 124 2-s2.0-0029900602
11. Legrand E., Aceclofenac in the management of inflammatory pain. Expert Opinion on Pharmacotherapy 2004 5 6 1347 1357 2-s2.0-3042771814 10.1517/14656566.5.6.1347 (Pubitemid 38885794)
12. Morros R., Figueras A., Capella D., Laporte J., Hypersensitivity vasculitis related to aceclofenac. The British Journal of Rheumatology 1997 36 4 503 504 2-s2.0-0030785753
13. Buján J. J. G., Alvarez-Eire G. M. G., Martinez W., del Pozo J., Fonseca E., Photoallergic contact dermatitis from aceclofenac. Contact Dermatitis 2001 45 3 170 2-s2.0-0034874834 10.1034/j.1600-0536.2001.045003170.x (Pubitemid 32800369)
14. Ludwig C., Brinkmeier T., Frosch P. J., Erythema multiforme exudativum with transition to toxic epidermal necrolysis after taking aceclofenac (Beofenac). Deutsche Medizinische Wochenschrift 2003 128 10 487 490 2-s2.0-0037424021 10.1055/s-2003-37627 (Pubitemid 36349814)
15. Rojas-Hijazo B., Garcés M., Ferrer L., Lezaun A., Colás C., Anaphylactic reaction after aceclofenac intake. Allergy 2006 61 4 511 2-s2.0-33644698675 10.1111/j.1398-9995.2006.01045.x (Pubitemid 43334126)
16. Gupta M., Cruz S. D., Nada R., Aggarwal P., Aceclofenac-induced acute tubulointerstitial nephritis in a patient with diabetes. BMJ Case Reports 2013 2-s2.0-84878986989 10.1136/bcr-2013-009217
17. Yamazaki R., Kawai S., Matsuzaki T., Kaneda N., Hashimoto S., Yokokura T., Okamoto R., Koshino T., Mizushima Y., Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. European Journal of Pharmacology 1997 329 2-3 181 187 2-s2.0-0030922754 10.1016/S0014-2999(97)10130-3 (Pubitemid 27270532)
18. Dannhardt G., Ulbrich H., In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detection using bovine aortic coronary endothelial cells (BAECs). Inflammation Research 2001 50 5 262 269 2-s2.0-0035012251 10.1007/s000110050752 (Pubitemid 32453012)
19. González-Alvaro I., Carmona L., Díaz-González F., González-Amaro R., Mollinedo F., Sánchez-Madrid F., Laffón A., García-Vicuña R., Aceclofenac, a new nonsteroidal antiinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. Journal of Rheumatology 1996 23 4 723 729 2-s2.0-0029875122 (Pubitemid 26139638)
20. Akimoto H., Yamazaki R., Hashimoto S., Sato T., Ito A., 4′-Hydroxy aceclofenac suppresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. European Journal of Pharmacology 2000 401 3 429 436 2-s2.0-0034637288 10.1016/S0014-2999(00)00472-6 (Pubitemid 30608729)
21. Yamazaki R., Kawai S., Matsumoto T., Matsuzaki T., Hashimoto S., Yokokura T., Okamoto R., Koshino T., Mizushima Y., Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. Journal of Pharmacology and Experimental Therapeutics 1999 289 2 676 681 2-s2.0-0032903184 (Pubitemid 29191218)
22. Henrotin Y., de Leval X., Mathy-Hartet M., Mouithys-Mickalad A., Deby-Dupont G., Dogné J., Delarge J., Reginster J., In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflammation Research 2001 50 8 391 399 2-s2.0-0034887381 (Pubitemid 32777665)
23. Maneiro E., López-Armada M. J., Fernández-Sueiro J. L., Lema B., Galdo F., Blanco F. J., Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. Journal of Rheumatology 2001 28 12 2692 2699 2-s2.0-0035203728 (Pubitemid 33135657)
24. Riley G. P., Cox M., Harrall R. L., Clements S., Hazleman B. L., Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro. Journal of Hand Surgery 2001 26 3 224 228 2-s2.0-0034954674 10.1054/jhsb.2001.0560 (Pubitemid 32586300)
25. Pareek A., Chandurkar N., Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Current Medical Research and Opinion 2013 29 7 849 859 2-s2.0-84880276567 10.1185/03007995.2013. 795139
26. Pareek A., Chandurkar N., Gupta A., Sirsikar A., Dalal B., Jesalpura B., Mehrotra A., Mukherjee A., Efficacy and safety of aceclofenac-CR and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. Journal of Pain 2011 12 5 546 553 2-s2.0-79955599517 10.1016/j.jpain.2010.10.013
27. Hooper L., Brown T. J., Elliott R. A., Payne K., Roberts C., Symmons D., The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. The British Medical Journal 2004 329 7472 948 952 2-s2.0-7044232909 10.1136/bmj.38232.680567.EB (Pubitemid 39422910)
28. Heyneman C. A., Lawless-Liday C., Wall G. C., Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000 60 3 555 574 2-s2.0-0033778512
29. Soni T., Nagda C., Gandhi T., Chotai N. P., Development of discriminating method for dissolution of aceclofenac marketed formulations. Dissolution Technologies 2008 15 2 31 35 2-s2.0-70350661431
30. Arslan S. A., Tirnaksiz F. A., A nonsteroidal antiinflammatory drug: aceclofenac. FABA Journal of Pharmaceutical Sciences 2010 35 2 105 118 2-s2.0-84875478223
31. Bhinge J. R., Kumar R. V., Sinha V. R., A simple and sensitive stability-indicating RP-HPLC assay method for the determination of aceclofenac. Journal of Chromatographic Science 2008 46 5 440 444 2-s2.0-43449108018 (Pubitemid 351669009)
32. Hasan N. Y., Abdel-Elkawy M., Elzeany B. E., Wagieh N. E., Stability indicating methods for the determination of aceclofenac. Il Farmaco 2003 58 2 91 99 2-s2.0-0037321026 10.1016/S0014-827X(02)01271-5 (Pubitemid 36197644)
33. Goud N. R., Suresh K., Nangia A., Solubility and stability advantage of aceclofenac salts. Crystal Growth and Design 2013 13 4 1590 1601 2-s2.0-84875779288 10.1021/cg301825u
34. Ward D. E., Veys E. M., Bowdler J. M., Roma J., Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clinical Rheumatology 1995 14 6 656 662 2-s2.0-0028806461 10.1007/BF02207932
35. Katare O., Raza K., Singh B., Dogra S., Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian Journal of Dermatology, Venereology and Leprology 2010 76 6 612 621 2-s2.0-78649309082 10.4103/0378-6323.72451
36. Raza K., Singh B., Lohan S., Sharma G., Negi P., Yachha Y., Katare O. P., Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. International Journal of Pharmaceutics 2013 456 1 65 72 2-s2.0-84883257498 10.1016/j.ijpharm.2013.08.019
37. Guy R. H., Current status and future prospects of transdermal drug delivery. Pharmaceutical Research 1996 13 12 1765 1769 2-s2.0-0030476053 10.1023/A:1016060403438 (Pubitemid 27034105)
38. Okyar A., Nuriyev M., Yildiz A., Pala-Kara Z., Ozturk N., Kaptan E., The effect of terpenes on percutaneous absorption of tiaprofenic acid gel. Archives of Pharmacal Research 2010 33 11 1781 1788 2-s2.0-78751548695 10.1007/s12272-010-1110-8
39. Barry B. W., Novel mechanisms and devices to enable successful transdermal drug delivery. European Journal of Pharmaceutical Sciences 2001 14 2 101 114 2-s2.0-0034902043 10.1016/S0928-0987(01)00167-1 (Pubitemid 32737532)
40. Raza K., Katare O. P., Setia A., Bhatia A., Singh B., Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. Journal of Microencapsulation 2013 30 3 225 236 2-s2.0-84874302972 10.3109/02652048.2012.717115
41. Bhatia A., Singh B., Wadhwa S., Raza K., Katare O. P., Novel phospholipid-based topical formulations of tamoxifen: evaluation for antipsoriatic activity using mouse-tail model. Pharmaceutical Development Technology 2014 19 2 160 163 10.3109/10837450.2013.763260
42. Raza K., Singh B., Singla N., Negi P., Singal P., Katare O. P., Nano-lipoidal carriers of isotretinoin with anti-aging potential: formulation, characterization and biochemical evaluation. Journal of Drug Targeting 2013 21 5 435 442 2-s2.0-84877254798 10.3109/1061186X.2012.761224
43. Bhatia A., Singh B., Raza K., Wadhwa S., Katare O. P., Tamoxifen-loaded lecithin organogel (LO) for topical application: development, optimization and characterization. International Journal of Pharmaceutics 2013 444 1-2 47 59 2-s2.0-84873700813 10.1016/j.ijpharm.2013.01.029
44. Raza K., Singh B., Singal P., Wadhwa S., Katare O. P., Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids and Surfaces B: Biointerfaces 2013 105 67 74 2-s2.0-84873192345 10.1016/j.colsurfb.2012.12.043
45. Raza K., Singh B., Singla S., Wadhwa S., Garg B., Chhibber S., Katare O. P., Nanocolloidal carriers of isotretinoin: antimicrobial activity against propionibacterium acnes and dermatokinetic modeling. Molecular Pharmaceutics 2013 10 5 1958 1963 2-s2.0-84877276974 10.1021/mp300722f
46. Sharma S., Lohan S., Murthy R. S., Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Development and Industrial Pharmacy 2013 10.3109/03639045.2013.789051
47. Hurler J., Sorensen K. K., Fallarero A., Vuorela P., Skalko-Basnet N., Liposomes-in-hydrogel delivery system with mupirocin: in vitro antibiofilm studies and in vivo evaluation in mice burn model. BioMed Research International 2013 2013 8 498485 10.1155/2013/498485
48. Ghanbarzadeh S., Arami S., Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes. BioMed Research International 2013 2013 7 2-s2.0-84881489352 10.1155/2013/616810 616810
49. Bhatia A., Singh B., Raza K., Shukla A., Amarji B., Katare O. P., Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis. Journal of Drug Targeting 2012 20 6 544 550 2-s2.0-84861838104 10.3109/1061186X.2012.694887
50. Shishu, Kamalpreet, Maheshwari M., Development and evaluation of novel microemulsion based oral formulations of 5-fluorouracil using non-everted rat intestine sac model. Drug Development and Industrial Pharmacy 2012 38 3 294 300 2-s2.0-84856446034 10.3109/03639045.2011.602407
51. Raza K., Negi P., Takyar S., Shukla A., Amarji B., Katare O. P., Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies. Journal of Microencapsulation 2011 28 3 190 199 2-s2.0-79953051360 10.3109/02652048.2010. 546435
52. Raza K., Singh B., Mahajan A., Negi P., Bhatia A., Katare O. P., Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. Journal of Drug Targeting 2011 19 4 293 302 2-s2.0-79953007356 10.3109/1061186X.2010.499464
53. Shukla A., Singh B., Katare O. P., Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes. The British Journal of Pharmacology 2011 164 2 820 827 2-s2.0-80052238985 10.1111/j.1476-5381.2011.01452.x
54. Jain A., Agarwal A., Majumder S., Lariya N., Khaya A., Agrawal H., Majumdar S., Agrawal G. P., Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. Journal of Controlled Release 2010 148 3 359 367 2-s2.0-78649786387 10.1016/j.jconrel.2010.09.003
55. Morganti P., Ruocco E., Wolf R., Ruocco V., Percutaneous absorption and delivery systems. Clinics in Dermatology 2001 19 4 489 501 2-s2.0-0034842093 10.1016/S0738-081X(01)00183-3 (Pubitemid 32842850)
56. Desai P., Patlolla R. R., Singh M., Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Molecular Membrane Biology 2010 27 7 247 259 2-s2.0-78049345788 10.3109/09687688.2010. 522203
57. Onoue S., Yamada S., Chan H. K., Nanodrugs: pharmacokinetics and safety. International Journal of Nanomedicine 2014 9 1025 1037
58. Lopes L. B., Overcoming the cutaneous barrier with microemulsions. Pharmaceutics 2014 6 1 52 77
59. Fairhurst D., Lee R. W., Observations on nanotechnology-based drug delivery approaches: translating nanotechnology from bench to pharmaceutical market: barriers, success, and promises. The American Pharmaceutical Review 2012 127536
60. Koudelka S., Turánek J., Liposomal paclitaxel formulations. Journal of Controlled Release 2012 163 3 322 334 2-s2.0-84867366635 10.1016/j.jconrel.2012.09.006
61. Clemons K. V., Capilla J., Sobel R. A., Martinez M., Tong A., Stevens D. A., Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits. Antimicrobial Agents and Chemotherapy 2009 53 5 1858 1862 2-s2.0-66149112447 10.1128/AAC.01538-08
62. Singh A. K., Narsipur S. S., Cyclosporine: a commentary on brand versus generic formulation exchange. Journal of Transplantation 2011 2011 6 480642 10.1155/2011/480642
63. Pardeike J., Hommoss A., Müller R. H., Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. International Journal of Pharmaceutics 2009 366 1-2 170 184 2-s2.0-57849099131 10.1016/j.ijpharm.2008.10. 003
64. Kim S., Liposomes as carriers of cancer chemotherapy: current status and future prospects. Drugs 1993 46 4 618 638 2-s2.0-0027495708 (Pubitemid 23331062)
65. Booser D. J., Hortobagyi G. N., Anthracycline antibiotics in cancer therapy: focus on drug resistance. Drugs 1994 47 2 223 258 2-s2.0-0027977771
66. Barber R., Shek P., Rolland A., Liposomes as a topical ocular drug delivery system. Pharmaceutical Particulate Carriers 1993 New York, NY, USA Marcel Dekker 1 20
67. Nasr M., Mansour S., Mortada N. D., Elshamy A. A., Vesicular aceclofenac systems: a comparative study between liposomes and niosomes. Journal of Microencapsulation 2008 25 7 499 512 2-s2.0-54049121401 10.1080/ 02652040802055411
68. Godin B., Touitou E., Ethosomes: new prospects in transdermal delivery. Critical Reviews in Therapeutic Drug Carrier Systems 2003 20 1 63 102 2-s2.0-0043212351 10.1615/CritRevTherDrugCarrierSyst.v20.i1.20 (Pubitemid 36929628)
69. Lewis S., Dave V., Aceclofenac ethosomes for enhanced transdermal delivery. Proceedings of the International Conference on Biomedical and Pharmaceutical Engineering (ICBPE '09) December 2009 Singapore 1 4 2-s2.0-77950843217 10.1109/ICBPE.2009.5384096
70. Dave V., Kumar D., Lewis S., Paliwal S., Ethosome for enhanced transdermal drug delivery of aceclofenac. International Journal of Drug Delivery 2010 2 2 81 92 10.5138/ijdd.2010.0975.0215.02016
71. Barupal A. K., Gupta V., Ramteke S., Preparation and characterization of ethosomes for topical delivery of aceclofenac. Indian Journal of Pharmaceutical Sciences 2010 72 5 582 586 2-s2.0-79955080935 10.4103/0250-474X.78524
72. Garg A. K., Negi L. M., Chauhan M., Gel containing ethosomal vesicles for transdermal delivery of aceclofenac. International Journal of Pharmacy and Pharmaceutical Sciences 2010 2 2 102 108 2-s2.0-77953348901
73. Shafiq S., Shakeel F., Talegaonkar S., Ahmad F. J., Khar R. K., Ali M., Design and development of oral oil in water ramipril nanoemulsion formulation: in vitro and in vivo assessment. Journal of Biomedical Nanotechnology 2007 3 1 28 44 2-s2.0-34548763353 10.1166/jbn.2007.008 (Pubitemid 351877125)
74. Yang J. H., Kim Y. I., Kim K. M., Preparation and evaluation of aceclofenac microemulsion for transdermal delivery system. Archives of Pharmacal Research 2002 25 4 534 540 2-s2.0-0036691910
75. Lee J., Lee Y., Kim J., Yoon M., Choi Y. W., Formulation of microemulsion systems for transdermal delivery of aceclofenac. Archives of Pharmacal Research 2005 28 9 1097 1102 2-s2.0-26444474819 (Pubitemid 41426859)
76. Shah R. R., Magdum C. S., Patil S. S., Niakwade N. S., Preparation and evaluation of aceclofenac topical microemulsion. Iranian Journal of Pharmaceutical Research 2010 9 1 5 11 2-s2.0-77949496604
77. Shakeel F., Baboota S., Ahuja A., Ali J., Aqil M., Shafiq S., Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech 2007 8 4 191 199 10.1208/pt0804104 2-s2.0-37349108788
78. Dasgupta S., Dey S., Choudhury S., Mazumder B., Topical delivery of aceclofenac as nanoemulsion comprising excipients having optimum emulsification capabilities: preparation, characterization and in vivo evaluation. Expert Opinion on Drug Delivery 2013 10 4 411 420 2-s2.0-84875180836 10.1517/17425247.2013.749234
79. Yoshioka A. T., Sternberg B. B., Florence A. T., Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). International Journal of Pharmaceutics 1994 105 1 1 6 2-s2.0-0028350410 10.1016/0378-5173(94)90228-3 (Pubitemid 24087666)
80. Vora B., Khopade A. J., Jain N. K., Proniosome based transdermal delivery of levonorgestrel for effective contraception. Journal of Controlled Release 1998 54 2 149 165 2-s2.0-0031855617 10.1016/S0168-3659(97)00100-4 (Pubitemid 28342694)
81. Solanki A. B., Parikh J. R., Parikh R. H., Patel M. R., Evaluation of different compositions of niosomes to optimize aceclofenac transdermal delivery. Asian Journal of Pharmaceutical Sciences 2010 5 3 87 95 2-s2.0-78349266425
82. Solanki A., Parikh J., Parikh R., Preparation, characterization, optimization, and stability studies of aceclofenac proniosomes. Iranian Journal of Pharmaceutical Research 2008 7 4 237 246 2-s2.0-67549110934
83. Sahoo S., Kumar N., Bhattacharya C., Sagiri S. S., Jain K., Pal K., Ray S. S., Nayak B., Organogels: properties and applications in drug delivery. Designed Monomers and Polymers 2011 14 2 95 108 2-s2.0-79953810583 10.1163/138577211X555721
84. Shaikh I. M., Jadhav S. L., Jadhav K. R., Kadam V. J., Pisal S. S., Aceclofenac organogels: in vitro and in vivo characterization. Current Drug Delivery 2009 6 1 1 7 2-s2.0-61849096275 10.2174/156720109787048320
85. Shaikh I. M., Jadhav K. R., Gide P. S., Kadam V. J., Pisal S. S., Topical delivery of aceclofenac from lecithin organogels: preformulation study. Current Drug Delivery 2006 3 4 417 427 2-s2.0-33749544413 10.2174/156720106778559010 (Pubitemid 44534054)
86. Kamble S. R., Udapurkar P., Biyani K. R., Nakhat P. D., Yeole P. G., Development and characterisation of pluronic lecithin organogels as a topical delivery system for aceclofenac. Inventi Impact: NDDS 2012 2012 1
87. Nasr M., Mansour S., Mortada N. D., El Shamy A. A., Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. AAPS PharmSciTech 2008 9 1 154 162 2-s2.0-44849122618 10.1208/s12249-007-9028-2
88. Patel D., Dasgupta S., Dey S., Ramani Y. R., Ray S., Mazumder B., Nanostructured lipid carriers (NLC)-based gel for the topical delivery of aceclofenac: preparation, characterization, and in vivo evaluation. Scientia Pharmaceutica 2012 80 3 749 764 2-s2.0-84866509897 10.3797/scipharm.1202-12
89. Chawla V., Saraf S. A., Rheological studies on solid lipid nanoparticle based carbopol gels of aceclofenac. Colloids and Surfaces B: Biointerfaces 2012 92 293 298 2-s2.0-84856106056 10.1016/j.colsurfb.2011.12.006